What is the role of topical medications in the treatment of lentigo maligna melanoma?

Updated: Dec 19, 2019
  • Author: Winston W Tan, MD, FACP; Chief Editor: William D James, MD  more...
  • Print


Topical imiquimod 5% cream has been described in many studies to be effective in treating lentigo maligna, especially in patients who are not surgical candidates. Imiquimod is an immune response modifier that offers encouraging results, but further studies are needed to identify ideal treatment protocols.

A systematic review found that imiquimod monotherapy provides a 76% histologic and a 78% clinical clearance rate for lentigo maligna. The incidence of clinical recurrence was 2.3%. Both cumulative dose and treatment intensity affect tumor clearance; treatment with more than 60 total applications, or with more than five applications per week, was associated with a higher likelihood of histologic clearance. [20]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!